Genentech’s Merdad Parsey to Join Gilead as Chief Medical Officer

Merdad Parsey has been appointed chief medical officer of Gilead Sciences (NASDAQ: [[ticker:GILD]]). The Foster City, CA-based company said Parsey will start his new role on Nov. 1. He will join Gilead from Roche subsidiary Genentech, where he is senior vice president of early clinical development in the company’s Research and Early Development Group. His experience also includes positions at 3-V Biosciences, Sepracor, Regeneron (NASDAQ:[[ticker:REGN]]), and Merck (NYSE: [[ticker:MRK]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.